MEI Pharma to Present at Wedbush PacGrow Healthcare Conference
Live Webcast from New York on August 11th
Aug 4, 2015
SAN DIEGO, Aug. 4, 2015 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. Eastern time from Le Parker Meridien in New York. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in development for the treatment of advanced hematologic diseases. The Company is also developing ME-344, a novel mitochondrial inhibitor that showed evidence of single-agent activity in a Phase I dose-escalation study in refractory solid tumors. In addition, the Company initiated a first-in-human study of PWT143, a highly selective PI3K delta inhibitor, in June 2015. For more information, please visit www.meipharma.com.
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
SOURCE MEI Pharma, Inc.
For further information: Pete De Spain, Vice President, Investor Relations & Corporate Communications, (858) 792-3729, email@example.com